What Animal Studies Say About Lurbinectedin's Safety in Pregnancy
Animal studies show lurbinectedin's embryo-fetal toxicity. In rats and rabbits, intravenous doses at or above human equivalents caused maternal toxicity, decreased body weight, and embryo-fetal lethality, including total litter loss at higher doses. No formal fertility studies exist, but reduced corpora lutea and implants occurred in rats.[1][2]
How This Affects Pregnancy Labeling
Lurbinectedin's prescribing information assigns it Pregnancy Category Not Assigned, but warns of potential harm based on these findings and its genotoxic mechanism (binds DNA, inhibits cell division). It advises effective contraception during treatment and for 6 months after in women of reproductive potential, and 4 months in men.[1][2]
Human Data and Recommendations
No adequate human pregnancy data exists. Animal results limit extrapolation, but healthcare providers counsel patients on risks. It's not recommended during pregnancy; alternatives or discontinuation may be considered based on benefit-risk assessment.[1]
Related Concerns for Patients Planning Pregnancy
Fertility effects are unknown in humans. Women should avoid breastfeeding during treatment and for 72 hours after. Men face similar contraception needs due to sperm DNA damage potential.[1][2]
[1]: Zepzelca (lurbinecteddin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI-Final.pdf
[2]: FDA Label for Lurbinecteddin, Drugs@FDA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf